Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZ1V0E)

Drug Name
BIIB 022 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hepatocellular carcinoma 2C12.02 Phase 1 [1]
Non-small-cell lung cancer 2C25.Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMZ1V0E

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Antagonist [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 4.542 5.508 6.35 5.558
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Hepatocellular carcinoma
ICD Disease Classification 2C12.02
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027382)
2 A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25.